Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-7,310,000
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 18,400
- Avg volume
- 5,712
- Day's range
- $0.04 – $0.07
- Shares out
- —
- Stochastic %K
- 24%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene...
Show more
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 510 318 9098
- Website
- https://www.estrellabio.com
- Address
- 5858 Horton Street, Suite 170, EmeryVille, United States
Latest news
No headlines yet.
